Page last updated: 2024-08-21

arsenic trioxide and Agnogenic Myeloid Metaplasia

arsenic trioxide has been researched along with Agnogenic Myeloid Metaplasia in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's2 (50.00)2.80

Authors

AuthorsStudies
Fan, S; Li, WW; Mo, XD; Sui, XF; Wang, CL; Wang, FY; Xu, H1
Bai, Y; Dou, L; Li, D; Niu, J; Niu, X; Qin, L; Sun, K; Wei, S; Xiao, M; Zhang, L; Zhang, W; Zhou, P1
Advani, A; Bejanyan, N; Chan, J; Jankowska, A; Kalaycio, M; Maciejewski, JP; Mooney, L; Raza, A; Saunthararajah, Y; Sekeres, MA; Tiu, RV1
Chen, Y; Li, Z; Lu, Q1

Reviews

2 review(s) available for arsenic trioxide and Agnogenic Myeloid Metaplasia

ArticleYear
Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review.
    Medicine, 2022, Aug-12, Volume: 101, Issue:32

    Topics: Arsenic Trioxide; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis

2022
Acute promyelocytic leukemia with myelofibrosis: A case report and literature review.
    Medicine, 2021, Apr-02, Volume: 100, Issue:13

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Primary Myelofibrosis; Treatment Outcome; Tretinoin

2021

Trials

1 trial(s) available for arsenic trioxide and Agnogenic Myeloid Metaplasia

ArticleYear
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
    Cancer, 2012, Aug-15, Volume: 118, Issue:16

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Myelodysplastic-Myeloproliferative Diseases; Oxides; Primary Myelofibrosis; Thalidomide

2012

Other Studies

1 other study(ies) available for arsenic trioxide and Agnogenic Myeloid Metaplasia

ArticleYear
Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine.
    Leukemia research, 2012, Volume: 36, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Primary Myelofibrosis; Remission Induction; Survivors; Tretinoin

2012